

Feeling the Pressure



(as in Intracranial Pressure....)

Liz Kim, MSN, ACNS-BC, FAHA Advanced Practice Provider – Neurocritical Care Stanford Health Care

> May 15, 2017 World Live Neurovascular Conference



Disclosures

- Financial Disclosures:
 - None relevant to the clinical content being presented
 - Intermittent Stroke reviewer for The Joint Commission

- Unapproved/Usage Disclosure:
 - None

Outline

- Intracranial hemodynamics
 - CBF Cerebral blood flow
 - CPP Cerebral perfusion pressure
 - ICP Intracranial pressure
- Causes of increased ICP
- Signs and Symptoms of ICP
- Treatment
 - Emergency Neurological Life Support:
 - Intracranial Hypertension and Herniation Protocol
 - Hyperosmolar Therapy
 - Decompressive Craniectomy for Malignant MCA Infarcts



Intracranial Pressure

Skull is a fixed volume vault; skull by nature is non-compliant

ICP = sum of 3 components to total a fixed volume in the cranial vault



Non-compressible, but partially displaceable





<u>Monro-Kellie</u> <u>Doctrine</u>

Sum of the intracranial volumes of blood, brain, CSF, and other components is constant, and that an increase in any one of these must be offset by an equal decrease in another, or else pressure increases.

Normal: 5 - 15 mmHg

Intracranial hypertension: ICP > 20mmHg sustained for more than 5 minutes

Cerebral Dynamics: Cerebral Perfusion Pressure

Cerebral perfusion pressure (CPP)

Difference between the force driving blood into the brain and the force resisting movement of blood into the brain



Cerebral Dynamics: Cerebral Blood Flow

<u>Cerebral Blood Flow (CBF)</u> Amount of blood passing through 100g of brain tissue in 1 minute

CBF =

<u>Cerebral perfusion pressure</u> Cerebral vascular resistance

750ml/minute ~15% of cardiac output 50ml/min per 100g of brain tissue

Average: 50 Ischemia: < 18 – 20 Tissue death: < 8 – 10 Hyperemia: > 55 – 60

Autoregulatory mechanisms maintain a relatively constant CBF, despite changes in systemic parameters

Cerebral Dynamics: Cerebral Blood Flow



Tameen et al., 2013

Causes of Increase ICP

Intracranial (primary)	Extracranial (secondary)	Postoperative
Tumor	Airway obstruction	Mass lesion (hematoma) edema
Tramua (Epidural & Subdural hematomas & contusions)	Hypoxia or hypercarbia	Increased cerebral blood volume (vasodilation)
Non-traumatic intracranial hemorrhages	Posture (head rotation)	Disturbances of CSF
Ischemic stroke	Hyperpyrexia	
Hydrocephalus	Seizures	
Idiopathic or benign intracranial hypertension	Drug and metabolic derangements	
Other (eg, pseudotumor cerebri, pneumoencephalus, abscesses, cysts)	Others (eg, high-altitude cerebral edema, hepatic failure)	Rangel-Castello, et al., 2008

Confidential – For Discussion Purposes Only

INCREASED INTRACRANIAL PRESSURE

- Changes in LOC
- Eyes
 - Papilledema
 - Pupillary Changes
 - Impaired Eye Movement
 - Posturing
 - Decerebrate
 - Decorticate
 - Flaccid
- Decreased Motor Function
 - * Change in Motor Ability
 - Posturing

\$2007 Nursing Education Consultants, Inc.

Headache

- Seizures
 - Impaired Sensory & Motor Function
- Changes in Vital Signs:
 - Cushing's Triad:
 - •† Systolic B/P
 - | Pulse
 - Altered Resp Pattern
- Vomiting
- Changes in Speech
- Infants: Bulging Fontanels
 - Cranial Suture Separation
 - † Head Circumference
 - •High Pitched Cry

Signs of Increased ICP

"EARLY" →	"LATE"
Headache	Changes in level of consciousness or ↓ GCS or FOUR Score ≥ 2 points
Irritability	Ipsilesional change in pupillary size, shape and light-responsiveness
Vomiting	Contralesional hemiparesis (new or worsening)
Photophobia, nystagmus, diploplia	Contralesional change in pupillary size and ipsilesional hemiparesis (Kernohan's phenomenon)
Lethargy	Cushing's triad: 个 SBP (widened pulse pressure), bradycardia, irregular respirations
Seizure	ENLS

How do we measure ICP?



Source: Jesse B. Hall, Gregory A. Schmidt, John P. Kress: Principles of Critical Care, 4th Edition: www.accessmedicine.com Copyright © McGraw-Hill Education. All rights reserved.

http://accessmedicine.mhmedical.com/data/books/1340/hall4_ch86_fig-86-16.png

Herniation



Confidential - For Discussion Purposes Only

Treatment of Intracranial Pressure

- Think BIG heterogeneous population
- Step wide approach



ENLS: Tier 0 – Standard Measures



Confidential - For Discussion Purposes Only

ENLS: Tier 1



Hyperosmolar Therapy

Mannitol:

- Osmotic <u>diuretic</u>, drawing water out of edematous brain tissue
- Typically given as bolus of 0.25-1g/kg
- Caution/Contraindicated: hypovolemia, hypotension, renal failure, pulmonary edema
- Over time "opens" blood brain barrier and mannitol crosses, losing efficacy
- Monitoring: Serum osmolality q4-6 hours (< 320)

Hypertonic saline:

- Causes an osmotic gradient, drawing water out of edematous brain tissue
- Can be given as bolus or infusion, ranging from 3-23.4%
- Can result in plasma volume expansion (increases blood pressure and CPP) – can be used with hypotension/hypovolemia
- Requires an intact blood brain barrier
- Overtime can lead to electrolyte abnormalities such as hyperchloremic acidosis
- Monitoring: Serum Na levels q4-6 hours (<160)

Which is better???

Difficult question limited by small number and size of

In a true emergency, whichever you can obtain/administer the quickest!

trial

ENLS: Post Tier 1

If ICP stabilized with Tier 1 \rightarrow obtain a head CT

If not, move to Tier $2 \rightarrow obtain$ head CT

Consider adjusting ICP, MAP and CPP based on clinical context







Decompression

If failing medical management:

 Review surgical options
Evacuation of mass lesion or decompression craniectomy

If the patient is ineligible for surgery or too unstable for brain imaging, move to Tier 3





Confidential – For Discussion Purposes Only

Decompressive Craniectomy in Ischemic Stroke



- Malignant Middle Cerebral Artery Infarct
 - Distal ICA or proximal MCA trunk occlusion leading to a large MCA infarction (+/- ACA or PCA involvement) and poor collateral compensation
 - Mortality of 78%, due to transtentorial herniation and brain death, range 2-5 days

Hacke et al., 1996

Demographic & Clinical Predictors Malignant MCA Infarct

Predictor	# patients	Odds ratio or Sens/Spec	Studies
Younger age	192	OR 0.4 95% CI 0.3-0.6 p<0.0001	Jaramillo et al Neurology 2006
Female sex	192	OR 8.2 95% CI 2.7-25.2 p = 0.0003	Jaramillo et al Neurology 2006
NO prior infarcts	192	OR 0.2 95% CI 0.05-0.7 p= 0.01	Jaramillo et al Neurology 2006
History of HTN	201	OR 3.0 95% CI 1.2-7.6 p=0.02	Kasner et al, Stroke 2001
History of CHF	201	OR 2.1 95% CI 1.5-3.0 p=0.001	Kasner et al, Stroke 2001
Admission NIHSS >20 [>15 for non-dom hemisphere]	28	100% sens 78% spec	Oppenheim et al, Stroke 2000
Nausea and vomiting 1 st 24 hours	135	OR 5.1 95% CI 1.7-15.3 p=0.003	Krieger et al, Stroke 1999

Adapted from Wartenberg, 2012

Radiographic Predictors of Malignant MCA

Predictor	# patients	Odds ratio or Sens/Spec	Studies
Hypodensity on initial head CT > 50% MCA territory	135 201 36	OR 6.1, 95% CI 2.3-16.6, p=0.0004 OR 6.3, 95% CI 3.5-11.6, p = 0.001 OR 14.0, 95% CI 1.04-189.4, p=0.047	Krieger et al, Stroke 1999 Kasner et al, Stroke 2001 Manno et al, Mayo Clin Proc 2003
CT Hyperdense MCA sign	36	OR 21.6, 95% CI 3.5-130, p < 0.001	Manno et al, Mayo Clin Proc 2003
CT Anteroseptal shift ≥ 5 mm on follow up head CT <48 hrs	135	OR 10.9; 95% CI 3.2-37.6	Barber et al, Cerebrovasc Dis 2003
MRI DWI volume >145 mL within 14 hours	28	100% sens, 94% spec	Oppenheim et al, Stroke 2000
MRI DWI volume >82 mL within 6 hours of onset	140	52% sens, 98% spec	Thomalla et al, Ann Neuro 2010

Adapted from Wartenberg, 2012

2007 Pooled DECIMAL, DESTINY, HAMLET Analysis

DECIMAL, DESTINY, HAMLET trials pooled their data prior to each individual results completed and published

93 pts randomized <48 hours



Figure 1: Distributions of the scores on the mRS and death after 12 months for patients treated with or without decompressive surgery

Confidential – For Discussion Purposes Only

Conclusions:

one year in the

2014 AHA/ASA Recommendations for the Management of Cerebral and Cerebellar Infarction With Swelling

Neurosurgical Options: Recommendations

- 1. In patients <60 years of age with unilateral MCA infarctions that deteriorate neurologically within 48 hours despite medical therapy, decompressive craniectomy with dural expansion is effective. The effect of later decompression is not known, but it should be strongly considered (*Class I; Level of Evidence B*).
- 2. Although the optimal trigger for decompressive craniectomy is unknown, it is reasonable to use a decrease in level of consciousness and its attribution to brain swelling as selection criteria (*Class IIa; Level of Evidence A*).
- 3. The efficacy of decompressive craniectomy in patients >60 years of age and the optimal timing of surgery are uncertain (*Class IIb; Level of Evidence C*).
- 4. Suboccipital craniectomy with dural expansion should be performed in patients with cerebellar infarctions who deteriorate neurologically despite maximal medical therapy (*Class I; Level of Evidence B*).

Timing – 48 vs. 72 hours

Conclusions:

When evaluated dichotomously, the odds of discharge to institutional care and of a poor outcome did not differ at 48 hours after hospital admission, but increased when surgery was pursued after 72 hours.



Figure. Differences in the crude rates (and SE) in mortality, discharge to institutional care, and of a poor outcome stratified by the timing of surgery: within 48 hours (**A**) and within 72 hours (**B**). A poor outcome was defined using the Nationwide Inpatient Sample-subarachnoid hemorrhage outcome measure (death, tracheostomy and gastrostomy placement, or discharge to institutional care). Statistically significant differences from multivariable logistic regression are designated with an asterisk. DHC indicates decompressive hemicraniectomy.

Age: Greater than 60 years old????

Conclusions:

Hemicraniectomy increased survival without severe disability among patients 61 years of age or older with a malignant middle cerebral artery infarction.

The majority of survivors required assistance with most bodily needs.





The primary end point was survival without severe disability, defined as a score of 0 to 4 on the modified Rankin scale (range, 0 to 6, with 0 indicating no symptoms and 6 indicating death). The results shown are the probability estimates for all patients who underwent randomization (the intention-to-treat population). Panel A shows the biascorrected distribution of scores on the modified Rankin scale at 6 months. Panel B shows the raw distribution of Rankin scores at 12 months.

Quality of Life Outcomes



Confidential - For Discussion Purposes Only

Figure 2 Domain mean ± SD z values of quality of life, sleep quality and mental symptom load (all domains of the patients group are significantly different from the control group).

So.... What does this look like in practice?

Case Study

Confidential - For Discussion Purposes Only

Case Study - OSH Presentation

- 59 year old male with history of Afib (on AC), HTN, BPH, GERD presenting to outside hospital with right MCA syndrome 16 hours from LKN. Transferred for higher level of care.
 - Likely stroke etiology: Cardio embolic (History of Afib, with non-compliance on Xarelto, related to recent PNA)



OSH – Non-Contrast Head CT 12/21 @ 6:36pm

Case Study - Arrival



CT angiogram head and neck with and without contrast: 12/23/2016 2:38 am

- Arrived at 12:30am
- NIHSS at arrival: NIH of 17 (1 right gaze, 2 left VF, 2 left face, 4 left arm, 4 left leg, 2 sensory, 1 dysarthria, 1 neglect)
- Initial plan: 23% boluses q4h for goal Na of > 150 with q4 hour monitoring, OR in AM

Around 3:30a exam deteriorated with and was taken for decompression ~ 20-24 hours ₃₂ post stroke

Post Op



CT head without contrast : 12/23/2016 11:17 am

Follow up



CT head with and without contr ast: 1/30/2017 7:16 pm

Stroke Clinic:

- 5 months post stroke living at SNF with biweekly rehab, will soon be moving in with son
- Full PO diet, not using PEG
- NIHSS: 11 (1 left VF, 1 left face, 4 left arm, 3 left leg, 1 sensory, 1 dysarthria)

References

- Dasenbrock, H.H., Robertson, F.C., Vaitkevicius, H., Aziz-Sultan, M.A., Guttieres, D., Dunn, I.F. ... Gormley, W.B. (2017). Timing of decompressive hemicraniectomy for stroke: A nationwide inpatient sample analysis. *Stroke, 48.* DOI: 10.1161/STROKEAHA.116.014727.
- Hacke, W., Schwab, S., Horn, M., Sprager, M., DeGeorgia, M., von Kummer, R. (1996). "Malignant" middle cerebral artery territory infraction: Clinical course and prognostic signs. Arch Neurol, 53, 309-315.
- Juttler, E., Unterberg, A., Woitzik, J., Bosel, J., Amiri, H., Sakowitz, O.W. ... Hacke, W. (2014). Hemicraniectomy in older patients with extensive middle-cerebral artery stroke. *The New England Journal of Medicine*, 370(12), 1091 -1100.
- Kamel, H., Navi, B.B., Nakagawa, K., Hemphill, J.C., Ko, N.U. (2011). Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: A meta-analysis of randomized clinical trials. *Critical Care Medicine, 39*(3), 554-559.
- Tameen, A. & Krowidi, H. (2013). Cerebral physiology. Contin Educ Anaseth Critical Care Pain, 13(4), 113-118., 26(2), 521-541.
- Rangel-Castillo, L., Gopinath, S., Robertson, C.S. (2008). Management of intracranial hypertension. Neurol Clin
- Stevens, R.D., Shoykhet, M., & Candena, R. (2015). Emergency Neurological Life Support: Intracranial hypertension and herniation. *Journal of Neurocritical Care, Suppl* 2:S76-82. doi: 10.1007/s12028-015-0168-z.
- Vahedi, K., Hofmeijer, J., Juettler, E., Vicaut, E., George, B., Algra, A. ... Hacke, W. (2007). Early decompressive surgery n the malignant infarction of the middle cerebral artery: a pooled analysis of three randomized controlled trials. *Lancet Neurol, 6,* 215–22. DOI:10.1016/S1474-4422(07)70036-4
- Wartenberg, K.E. (2012). Malignant middle cerebral artery infarction. *Curr Opin Crit Care, 18*:152–163.
- Wijdicks, E.F.M., Sheth, K.N., Carter, B.S., Greer, D.M., Kasner, S.E., Kimberly, T. ... Wintermark, M. (2014). Recommendations for the managment of cerebral and cerebellar infarction with swelling: A statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke, 45,* 1222-1238.



ElizabethKim@stanfordhealthcare.org